Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23641056)

1.

Reversibility of structural and functional damage in a model of advanced diabetic nephropathy.

Pichaiwong W, Hudkins KL, Wietecha T, Nguyen TQ, Tachaudomdach C, Li W, Askari B, Kobayashi T, O'Brien KD, Pippin JW, Shankland SJ, Alpers CE.

J Am Soc Nephrol. 2013 Jun;24(7):1088-102. doi: 10.1681/ASN.2012050445. Epub 2013 May 2.

2.

BTBR Ob/Ob mutant mice model progressive diabetic nephropathy.

Hudkins KL, Pichaiwong W, Wietecha T, Kowalewska J, Banas MC, Spencer MW, Mühlfeld A, Koelling M, Pippin JW, Shankland SJ, Askari B, Rabaglia ME, Keller MP, Attie AD, Alpers CE.

J Am Soc Nephrol. 2010 Sep;21(9):1533-42. doi: 10.1681/ASN.2009121290. Epub 2010 Jul 15.

3.

The podocyte: a potential therapeutic target in diabetic nephropathy?

Marshall SM.

Curr Pharm Des. 2007;13(26):2713-20. Review.

PMID:
17897015
4.

Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.

Cheng H, Fan X, Moeckel GW, Harris RC.

J Am Soc Nephrol. 2011 Jul;22(7):1240-51. doi: 10.1681/ASN.2010111149.

5.

Mouse models of diabetic nephropathy.

Alpers CE, Hudkins KL.

Curr Opin Nephrol Hypertens. 2011 May;20(3):278-84. doi: 10.1097/MNH.0b013e3283451901. Review.

6.

Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.

Zhang M, Liu M, Xiong M, Gong J, Tan X.

J Ethnopharmacol. 2012 May 7;141(1):111-8. doi: 10.1016/j.jep.2012.02.007. Epub 2012 Feb 14.

PMID:
22353431
7.
8.

Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.

Herbach N, Schairer I, Blutke A, Kautz S, Siebert A, Göke B, Wolf E, Wanke R.

Am J Physiol Renal Physiol. 2009 Apr;296(4):F819-29. doi: 10.1152/ajprenal.90665.2008. Epub 2009 Feb 11.

9.

Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy.

Suganami T, Mukoyama M, Mori K, Yokoi H, Koshikawa M, Sawai K, Hidaka S, Ebihara K, Tanaka T, Sugawara A, Kawachi H, Vinson C, Ogawa Y, Nakao K.

FASEB J. 2005 Jan;19(1):127-9. Epub 2004 Oct 20.

10.

Loss of PTEN promotes podocyte cytoskeletal rearrangement, aggravating diabetic nephropathy.

Lin JS, Shi Y, Peng H, Shen X, Thomas S, Wang Y, Truong LD, Dryer SE, Hu Z, Xu J.

J Pathol. 2015 May;236(1):30-40. doi: 10.1002/path.4508. Epub 2015 Feb 19.

PMID:
25641678
11.

Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.

Veron D, Bertuccio CA, Marlier A, Reidy K, Garcia AM, Jimenez J, Velazquez H, Kashgarian M, Moeckel GW, Tufro A.

Diabetologia. 2011 May;54(5):1227-41. doi: 10.1007/s00125-010-2034-z. Epub 2011 Feb 12.

12.

Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice.

Zhang H, Schin M, Saha J, Burke K, Holzman LB, Filipiak W, Saunders T, Xiang M, Heilig CW, Brosius FC 3rd.

Am J Physiol Renal Physiol. 2010 Jul;299(1):F91-8. doi: 10.1152/ajprenal.00021.2010. Epub 2010 Apr 7.

13.

Renin-angiotensin system within the diabetic podocyte.

Márquez E, Riera M, Pascual J, Soler MJ.

Am J Physiol Renal Physiol. 2015 Jan 1;308(1):F1-10. doi: 10.1152/ajprenal.00531.2013. Epub 2014 Oct 22. Review.

PMID:
25339703
14.

Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.

Rüster C, Bondeva T, Franke S, Förster M, Wolf G.

Nephrol Dial Transplant. 2008 Jul;23(7):2179-91. doi: 10.1093/ndt/gfn085. Epub 2008 Mar 14.

15.

Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.

Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, Schreiner GF, Saleem MA, Mathieson PW, Makino H, Johnson RJ, Nakagawa T.

Am J Physiol Renal Physiol. 2012 May 1;302(9):F1151-60. doi: 10.1152/ajprenal.00596.2011. Epub 2012 Feb 15.

16.

eNOS deficiency predisposes podocytes to injury in diabetes.

Yuen DA, Stead BE, Zhang Y, White KE, Kabir MG, Thai K, Advani SL, Connelly KA, Takano T, Zhu L, Cox AJ, Kelly DJ, Gibson IW, Takahashi T, Harris RC, Advani A.

J Am Soc Nephrol. 2012 Nov;23(11):1810-23. doi: 10.1681/ASN.2011121170. Epub 2012 Sep 20.

17.

Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes.

Stieger N, Worthmann K, Teng B, Engeli S, Das AM, Haller H, Schiffer M.

Metabolism. 2012 Aug;61(8):1073-86. doi: 10.1016/j.metabol.2011.12.003. Epub 2012 Feb 24.

PMID:
22365040
18.

Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy.

Zheng S, Carlson EC, Yang L, Kralik PM, Huang Y, Epstein PN.

J Am Soc Nephrol. 2008 Nov;19(11):2077-85. doi: 10.1681/ASN.2007080967. Epub 2008 Jul 16.

19.

Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.

Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K, Iida M.

Nephrol Dial Transplant. 2011 Aug;26(8):2475-84. doi: 10.1093/ndt/gfq750. Epub 2011 Jan 10.

20.

Hypertrophy and loss of podocytes in diabetic nephropathy.

Miyauchi M, Toyoda M, Kobayashi K, Abe M, Kobayashi T, Kato M, Yamamoto N, Kimura M, Umezono T, Suzuki D.

Intern Med. 2009;48(18):1615-20. Epub 2009 Sep 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk